HALE DAVID F - 23 Feb 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Feb 2024
Net transaction value: +$8,859
SEC form: 4
Accepted by SEC: 27 Feb 2024, 17:03:15 UTC
Prior SEC filing: 05 Jan 2024
Next SEC filing: 24 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/Chase C. Leavitt, Attorney-in-fact

Key filing fact

HALE DAVID F filed Form 4 for Oncternal Therapeutics, Inc. on 27 Feb 2024.

Key facts

This page summarizes HALE DAVID F's Form 4 filing for Oncternal Therapeutics, Inc..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Feb 2024, 17:03.

Change

Previous filing in this sequence was filed on 05 Jan 2024.
Current net transaction value: +$8,859.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONCT transaction

Common Stock

Purchase

Transaction value: $6,455
Shares: +714
Change %
Price: $9.04
Shares after: 714
Date: 23 Feb 2024
Ownership: Direct
Footnotes: F1

ONCT transaction

Common Stock

Purchase

Transaction value: $2,405
Shares: +266
Change %: +0.9%
Price: $9.04
Shares after: 29,673
Date: 23 Feb 2024
Ownership: By Hale BioPharma Ventures, LLC
Footnotes: F1

ONCT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 917
Date: 23 Feb 2024
Ownership: By Hale Trading Company

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.

SEC remarks

The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.